Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ocuvite DF is a specialized dietary supplement developed by Bausch + Lomb specifically to support the ocular health of individuals with diabetes. The 'DF' designation stands for Diabetic Formula, reflecting a composition tailored to address the unique nutritional needs and increased oxidative stress associated with diabetic eye conditions. The formulation includes essential antioxidant vitamins (C and E), minerals (Zinc and Copper), and the macular carotenoids Lutein and Zeaxanthin, which help filter harmful blue light and maintain retinal integrity. Additionally, Ocuvite DF incorporates Alpha-lipoic acid and Genistein, compounds selected for their potential to mitigate metabolic stress and support vascular health in the eye. It is intended as a nutritional adjunct to support long-term vision health rather than a primary treatment for diabetic retinopathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ocuvite DF.